Evidence map›Paper›PMID 30128689›Full record

ArticleJournal of neuro-oncology2018

Rapid discrimination of pediatric brain tumors by mass spectrometry imaging.

Amanda R Clark, David Calligaris, Michael S Regan, Daniel Pomeranz Krummel, Jeffrey N Agar, Laura Kallay, Tobey MacDonald, Matthew Schniederjan, Sandro Santagata, Scott L Pomeroy and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 57 citations in OpenAlex.

  1. Review
  2. Topological segmentation of mass spectrometry imaging data.Journal of mass spectrometry and advances in the clinical lab · 2025
    Article
  3. Review
  4. Article
  5. Mass spectrometry in animal health laboratories: recent history, current applications, and future directions.Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc · 2024
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Amanda R ClarkDepartment of Neurosurgery, Brigham and Woman's Hospital, Harvard Medical School, 60 Fenwood Road, 8016-J, Boston, MA, 02115, USA.
David CalligarisDepartment of Neurosurgery, Brigham and Woman's Hospital, Harvard Medical School, 60 Fenwood Road, 8016-J, Boston, MA, 02115, USA.
Michael S ReganDepartment of Neurosurgery, Brigham and Woman's Hospital, Harvard Medical School, 60 Fenwood Road, 8016-J, Boston, MA, 02115, USA.
Daniel Pomeranz KrummelWinship Cancer Institute, Emory University School of Medicine, 1365C Clifton Road, Suite C5086, Atlanta, GA, 30322, USA.
Jeffrey N AgarDepartments of Chemistry and Pharm. Sci., Barnett Institute, Northeastern University, Boston, MA, USA.
Laura KallayDepartment of Neurology, Emory University School of Medicine, Atlanta, GA, USA.
Tobey MacDonaldWinship Cancer Institute, Emory University School of Medicine, 1365C Clifton Road, Suite C5086, Atlanta, GA, 30322, USA.
Matthew SchniederjanDepartment of Pathology and Laboratory Medicine, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA, USA.
Sandro SantagataDepartment of Pathology, Brigham and Woman's Hospital, Harvard Medical School, Boston, MA, USA.
Scott L PomeroyDepartment of Neurology, Harvard Medical School, Boston Children's Hospital, Boston, MA, USA.
Nathalie Y R AgarDepartment of Neurosurgery, Brigham and Woman's Hospital, Harvard Medical School, 60 Fenwood Road, 8016-J, Boston, MA, 02115, USA. Nathalie_Agar@dfci.harvard.edu.
Soma SenguptaWinship Cancer Institute, Emory University School of Medicine, 1365C Clifton Road, Suite C5086, Atlanta, GA, 30322, USA. soma.sengupta@emory.edu.ORCID http://orcid.org/0000-0003-4577-1397
Emory University · USHarvard University · USBoston Children's Hospital · USEmory Healthcare · USNortheastern University · US

Funding

Training in Pharmacological SciencesT32GM007306 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI GOLAN, DAVID E. · 1985 to 2018
$6.6M
Elucidating Signaling Pathways for GABA-A Receptor Alpha5 in an Aggressive Subtype of MedulloblastomasK08NS083626 · NINDS · EMORY UNIVERSITY · PI SENGUPTA, SOMA · 2014 to 2018
$741k
American Cancer Society RG-14-188-01NIGMS NIH HHS T32 GM007306NIH HHS T32 GM 7306-42NINDS NIH HHS K08 NS083626
6 · The paper itself

Abstract

purposeMedulloblastoma, the most common primary pediatric malignant brain tumor, originates in the posterior fossa of the brain. Pineoblastoma, which originates within the pineal gland, is a rarer malignancy that also presents in the pediatric population. Medulloblastoma and pineoblastoma exhibit overlapping clinical features and have similar histopathological characteristics. Histopathological similarities confound rapid diagnoses of these two tumor types. We have conducted a pilot feasibility study analyzing the molecular profile of archived frozen human tumor specimens using mass spectrometry imaging (MSI) to identify potential biomarkers capable of classifying and distinguishing between medulloblastoma and pineoblastoma.

methodsWe performed matrix-assisted laser desorption ionization Fourier transform ion cyclotron resonance mass spectrometry imaging on eight medulloblastoma biopsy specimens and three pineoblastoma biopsy specimens. Multivariate statistical analyses were performed on the MSI dataset to generate classifiers that distinguish the two tumor types. Lastly, the molecules that were discriminative of tumor type were queried against the Lipid Maps database and identified.

resultsIn this pilot study we show that medulloblastoma and pineoblastoma can be discriminated using molecular profiles determined by MSI. The highest-ranking discriminating classifiers of medulloblastoma and pineoblastoma were glycerophosphoglycerols and sphingolipids, respectively.

conclusionWe demonstrate proof-of-concept that medulloblastoma and pineoblastoma can be rapidly distinguished by using MSI lipid profiles. We identified biomarker candidates capable of distinguishing these two histopathologically similar tumor types. This work expands the current molecular knowledge of medulloblastoma and pineoblastoma by characterizing their lipidomic profiles, which may be useful for developing novel diagnostic, prognostic and therapeutic strategies.

Indexed as

Spectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationBrain NeoplasmsCerebellumChildDiagnosis, DifferentialHumansMedulloblastomaPilot ProjectsPineal GlandPinealomaProof of Concept StudyBiomarkersBrain tumorsLipidsMass spectrometry imagingMedulloblastomaPineoblastoma

Identifiers

PMID30128689
PMCPMC6244779
OpenAlexW2888482961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.